
Please try another search
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Name | Age | Since | Title |
---|---|---|---|
Norman David Eansor | 64 | 2018 | Independent Chairman |
Malcolm K. Brenner | 72 | 2018 | Member of Scientific Advisory Board |
Juan F. Vera | 45 | 2018 | Co-Founder, CEO, President, Treasurer, Secretary & Director |
Helen E. Heslop | - | 2018 | Member of Scientific Advisory Board |
Katharine Knobil | 60 | 2021 | Independent Director |
Cliona M. Rooney | - | 2018 | Member of Scientific Advisory Board |
Steven Arnote Elms | 62 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review